AgroSource, Inc. v. TJ Biotech: Federal Circuit Dismissal in Landmark Ag-Bio Patent Case
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | AgroSource, Inc. v. TJ Biotech, LLC |
| Case Number | 26-1328 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from District Court (via D.C. Circuit) |
| Duration | Jan 2026 – Feb 2026 31 Days |
| Outcome | Voluntary Dismissal — Costs Each Side |
| Patents at Issue | |
| Accused Products | Antimicrobial Plant Treatments / Agri-Biotech Products |
Case Overview
The Parties
⚖️ Plaintiff
Patent holder focused on antimicrobial compositions and methods for treating plant diseases within the agricultural biologicals market.
🛡️ Defendant
Biotechnology entity whose products or processes were alleged to infringe the asserted patent claims.
Patents at Issue
This case centered on U.S. Patent No. 12382956B2, covering antimicrobial compositions and methods for treating plant diseases. This technology area is critical in agricultural biotechnology, especially as the sector increasingly relies on biological and biochemical crop protection alternatives.
- • US12382956B2 — Antimicrobial compositions and methods for treating plant diseases
Developing a new ag-bio product?
Check if your antimicrobial plant treatment might infringe this or related patents before launch.
The Verdict & Legal Analysis
Outcome
The Federal Circuit ordered the proceeding dismissed under Fed. R. App. P. 42(b) based on the mutual agreement of both parties. Critically, the court ordered that each side bear its own costs — a standard but strategically meaningful provision indicating neither party extracted a fee-shifting concession from the other. No damages award, no injunctive relief, and no judicial ruling on the merits were issued.
Key Legal Issues
The rapid 31-day resolution suggests that settlement negotiations were substantially advanced before the appeal was filed, or that strategic weaknesses in an appellate position became apparent. The dismissal being voluntary and pre-merits carries no precedential value on the merits. The absence of a written opinion means US12382956B2’s claim scope, validity, and infringement standards remain unaddressed by the appellate court. This is a legally neutral outcome for the patent’s enforceability posture — the patent remains in force, and no estoppel arising from this proceeding would ordinarily bind the parties on unlitigated claims.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in antimicrobial plant treatment. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View the patent family and related technology space
- See which companies are active in plant health patents
- Understand claim construction patterns in ag-bio
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own ag-bio technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Antimicrobial plant treatment compositions
Related Patent Families
In antimicrobial plant treatment
Early Detection Key
FTO analysis is crucial before product launch
✅ Key Takeaways
Voluntary Federal Circuit dismissals under Rule 42(b) within 30 days of filing frequently signal pre-negotiated settlements or leverage-based filings — analyze docketing strategy accordingly.
Search related case law →US12382956B2 remains an active, unadjudicated enforcement asset in the antimicrobial plant treatment space.
Explore precedents →Cost-neutrality provisions in appellate stipulations reflect negotiating equilibrium — document this pattern across agricultural biotech settlements.
Analyze settlement patterns →Frequently Asked Questions
The case involved U.S. Patent No. 12382956B2 (Application No. US17/516229), directed to antimicrobial compositions and methods for treating plant diseases.
The parties mutually agreed to dismiss the Federal Circuit appeal under Fed. R. App. P. 42(b), with each side bearing its own costs. No merits ruling was issued.
The dismissal leaves US12382956B2 valid and enforceable with no Federal Circuit claim construction guidance, meaning the patent’s scope remains available for future assertion or licensing.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States Court of Appeals for the Federal Circuit — Case 26-1328
- U.S. Patent and Trademark Office — Patent Center (US12382956B2)
- Cornell Legal Information Institute — Fed. R. App. P. 42
- PatSnap — IP Intelligence Solutions for Agri-Biotech
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.